zhengguangmycin and Esophageal-Neoplasms

A prospective randomized trial in 64 esophageal cancer patients was conducted from 1986 to 1989. The patients were randomized into two groups-PPF (DDP 100 mg/m2 + pingyangmycin + 5-FU) regimen plus radiotherapy (combined group) or radiotherapy alone (control group). The overall response rate and CR rate in the combined group were 87.5% (28/32) and 40.6% (13/32). Those of the control group were 81.3% (26/32) and 21.9% (7/32), respectively. The overall response rates were similar in these two groups, but the CR rate in the combined groups was higher than that of the control group. The 1-year survival rates in the combined and control groups were 77.4% (24/31) and 45.2% (14/31) (p less than 0.01). The 2-year survival rates were 56.3% (9/16) and 34.6% (9/26), respectively (p greater than 0.05). Our preliminary results show that combined chemotherapy including high dose cisplatin and radiotherapy may improve the therapeutic result of esophageal cancer.

Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Cobalt Radioisotopes; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Prospective Studies; Radioisotope Teletherapy

Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drugs, Chinese Herbal; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Mitomycin; Phytotherapy

Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorouracil; Humans; Injections, Intralesional; Male; Microwaves; Middle Aged; Mitomycins

Pingyangmycin (PYM), produced by Streptomyces pingyangensis n. sp., was found to be identical to bleomycin A5. In the present study, a comparative observation was carried out in 10 human cancer cell lines. As determined by a colony-forming assay, the dose-response curves obtained from cells exposed to PYM for 1 h were of one type only: biphasic exponential. The sensitivities of these cells derived from different types of tumors, however, varied with a broad range of ID50 values (0.03-0.82 microgram/ml). A hepatoma cell line (BEL-7402) and three lines derived from squamous carcinomas of the esophagus (Eca109 and CaEs17) or the nasopharynx (CNE) were relatively sensitive (ID50 less than 0.20 microgram/ml) to PYM which is known to have clinical activity against these diseases. Two gastric adenocarcinoma cell lines (MGc80-3 and BGC-823) and a pulmonary adenocarcinoma cell line (SPC-A-1) appeared to be less sensitive to the drug, with ID50 values of 0.21-0.47 microgram/ml. PYM was 7-fold more effective against LTEP-78 cells derived from pulmonary squamous carcinoma as opposed to SPC-A-1 cells, resulting in a low ID50 value of 0.04 microgram/ml. However, PYM as a single agent has not yet received full evaluation in relation to this type of lung cancer. In contrast with other cell lines of squamous cancer origin, HeLa and CC-801 cells derived from uterine cervix carcinomas which have been evaluated as highly responsive to PYM had the highest ID50 values (greater than 0.70 microgram/ml).

Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Bleomycin; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Humans; Liver Neoplasms; Lung Neoplasms; Nasopharyngeal Neoplasms; Tumor Cells, Cultured; Tumor Stem Cell Assay; Uterine Cervical Neoplasms

One hundred and fifteen patients with inoperable esophageal carcinoma were treated by either chemotherapy alone or chemotherapy plus Rabdosia rubescens. In group A, out of 31 patients treated with pingyangmycin (P) and nitrocaphane (N), 10 (32.3%) responded to the treatment. Among them, 2 showed partial response (greater than 50% tumor regression) and 8 minimal response (greater than 50% tumor regression). In group B, out of 84 patients treated with PN plus Rabdosia rubescens, 59 (70.2%) responded. Of them, 10 showed complete response (100% tumor regression), 16 partial response and 33 minimal response. the one-year survival rates of group A and B were 13.6% and 41.3%. Statistical significance was present in these two groups both in the response rate and one-year survival rate. As regards the drug toxicity, there was no significant difference between these two groups. Alopecia, anorexia, nausea and hyperpyrexia occurred in more than 30% of patients. Mild leukopenia and thrombocytopenia and interstitial pneumonia were noted in some patients, and two patients died of toxicity in the lungs.

Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Drug Synergism; Esophageal Neoplasms; Female; Humans; Male; Medicine, Chinese Traditional; Medicine, East Asian Traditional; Middle Aged; Nitrogen Mustard Compounds; Plant Extracts; Plants, Medicinal

Topics: Animals; Bleomycin; Carcinoma; Esophageal Neoplasms; Lethal Dose 50; Mice; Neoplasms, Experimental; Rats

Topics: Animals; Antibiotics, Antineoplastic; Bleomycin; Carcinoma 256, Walker; Dogs; Esophageal Neoplasms; Liver Neoplasms, Experimental; Melanoma; Mice; Neoplasms, Experimental; Rats; Sarcoma 180; Sarcoma 37

Topics: Antibiotics, Antineoplastic; Bleomycin; Carcinoma, Squamous Cell; Esophageal Neoplasms; Head and Neck Neoplasms; Humans; Lip Neoplasms; Tongue Neoplasms